China-based Harbour BioMed (HKG: 2142) announced a strategic partnership with Insilico Medicine, a generative artificial intelligence (AI)-driven biotech firm. The collaboration aims to leverage their respective strengths in antibody discovery and AI to accelerate the development of innovative therapeutic antibodies.
Partnership Details
The partnership combines Harbour BioMed’s industry-leading technology platform, proprietary dataset, and expertise in antibody development with Insilico’s advanced AI-driven drug discovery capabilities. The two companies plan to jointly develop next-generation AI-powered antibody applications.
Collaborative Efforts
In addition to developing AI-powered antibodies, the companies will collaborate on early-stage drug discovery programs targeting novel, specific antibodies. This collaboration will utilize Insilico’s AI expertise and Harbour BioMed’s wet lab capabilities to address unmet medical needs in immunology, oncology, and neuroscience.-Fineline Info & Tech
